

BIOTIME INC
Form 4
November 10, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
KINGSLEY ALFRED D

(Last) (First) (Middle)
150 E. 57TH STREET
(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOTIME INC [BTX]

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

See Remarks

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Common Shares, no par value	11/06/2015		S		100,000 (1)	D	\$ 3.83
Common Shares, no par value					5,938,055 (2)	D	
Common Shares, no par value					1,506,905	I	By Greenbelt Corp.
Common Shares, no par value					375,351	I	By Greenway Partners, LP

Edgar Filing: BIOTIME INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price or Value of Underlying Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Shares	\$ 3.57					<u>(3)</u>	06/30/2020	Common Shares	50,000
Option to Purchase Common Shares	\$ 3.11					<u>(4)</u>	06/30/2019	Common Shares	50,000
Option to Purchase Common Shares	\$ 4.13					<u>(5)</u>	06/30/2018	Common Shares	50,000
Option to Purchase Common Shares	\$ 4.6					<u>(6)</u>	06/30/2017	Common Shares	50,000
Option to Purchase Common Shares	\$ 5.13					<u>(7)</u>	06/30/2016	Common Shares	50,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

KINGSLEY ALFRED D
150 E. 57TH STREET X X See Remarks
NEW YORK, NY 10022

Signatures

/s/ Alfred D.
Kingsley 11/10/2015

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities were sold in a private transaction. Mr. Kingsley plans to invest the sale proceeds in Ascendance Biotechnology, Inc., a new subsidiary of BioTime.
 - (2) Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
 - (3) 12,500 options became exercisable on September 30, 2015 and the remaining 37,500 options will become exercisable in 3 equal quarterly installments based upon continued service on the board of directors.
 - (4) 12,500 options became exercisable on September 30, 2014; December 31, 2014; March 31, 2015; and June 30, 2015.
 - (5) 12,500 options became exercisable on September 30, 2013; December 31, 2013; March 31, 2014; and June 30, 2014.
 - (6) 12,500 options became exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013.
 - (7) 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

Remarks:

Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.